

"Express Mail" Label No. EV 338472317 US  
Date of Deposit November 14, 2003

PATENT  
Attorney Docket No.: 18649J-000420US

I hereby certify that this is being deposited with the United States Postal Service "Express Mail Post Office to Address" service under 37 CFR 1.10 on the date indicated above and is addressed to:

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

By: 

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re application of:

Min Michael He et al.

Application No.:

Filed:

For: NOVEL TABLETS  
INCORPORATING ISOFLAVONE  
PLANT EXTRACTS AND METHODS  
OF MANUFACTURING WATER  
SOLUBLE POLYMER-BASED  
RAPIDLY DISSOLVING TABLETS  
AND PRODUCTION PROCESSES  
THEREOF

Examiner:

Art Unit:

SUPPLEMENTAL INFORMATION  
DISCLOSURE STATEMENT UNDER 37  
CFR §1.97 and §1.98

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450


Sir:

The references cited on attached form PTO/SB/08A and PTO/SB/08B are being called to the attention of the Examiner. In accordance with 37 CFR §1.98(d), copies of the references can be found in Application No. 10/155,281, filed 05/23/02 (Attorney Docket No. 18649J-000410US). It is respectfully requested that the cited references be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

As provided for by 37 CFR 1.97(g) and (h), no inference should be made that the information and references cited are prior art merely because they are in this statement and no representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information.

Applicant believes that no fee is required for submission of this statement. However, if a fee is required, the Commissioner is authorized to deduct such fee from the undersigned's Deposit Account No. 20-1430. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,



Joseph R. Snyder  
Reg. No. 39,381

TOWNSEND and TOWNSEND and CREW LLP  
Two Embarcadero Center, Eighth Floor  
San Francisco, California 94111-3834  
Tel: 925-472-5000  
Fax: 925-472-8895  
JS:jc  
60081947 v1

<b>FORM PTO-1449 (Modified)</b> <b>LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)</b>			<b>Attorney Docket No.:</b> _____		<b>Application No.:</b> _____	
			<b>Applicant: Min Michael He et al:</b>			
			<b>Filing Date:</b> _____		<b>Group:</b> _____	
<b>Reference Designation</b>			<b>U.S. PATENT DOCUMENTS</b>			<b>Page 1</b>
<b>Examiner Initial</b>	<b>Document No.</b>	<b>Date</b>	<b>Name</b>	<b>Class</b>	<b>Sub-class</b>	<b>Filing Date (If Appropriate)</b>
____ AA						
____ AB						
____ AC						
____ AD						
____ AE						
____ AF						
____ AG						
____ AH						
____ AI						
____ AJ						
____ AK						
____ AL						
<b>FOREIGN PATENT DOCUMENTS</b>						
	<b>Document No.</b>	<b>Date</b>	<b>Country</b>	<b>Class</b>	<b>Sub-class</b>	<b>Translation (Yes/No)</b>
____ AM	DE 197 32 855 A1	0218/99	Indena	A61K	35/78	No
____ AN	DE 197 32 866 A1	02/18/99	Indena	A61K	3578	No
____ AO						
____ AP						
____ AQ						
____ AR						
<b>OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)</b>						
____ AS	Derwent Publication Ltd., Lodon, GB, Class A96, AN 1997-534403 XP002151122					
____ AT						
____ AU						
____ AV						
____ AW						
<b>EXAMINER</b>			<b>DATE CONSIDERED</b>			

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 (Modified)			Attorney Docket No.:		Application No.:	
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)			Applicant: Min Michael He, Fang-yu Liu, Joseph A. Fix, Martin Link, Maria L. Kang and Ezio Bombardelli			
			Filing Date:		Group:	
Reference Designation			U.S. PATENT DOCUMENTS			Page 1
Examiner Initial	Document No.	Date	Name	Class	Sub-class	Filing Date (If Appropriate)
AA	5,830,887	11/03/98	Kelly	514	182	
AB	5,674,548	10/07/97	Nakamura et.al.	426	598	
AC	5,855,892	01/05/99	Potter et. al.	424	195.1	
AD	5,858,449	01/12/99	Crank et. al.	426	656	
AE						
FOREIGN PATENT DOCUMENTS						
	Document No.	Date	Country	Class	Sub-class	Translation (Yes/No)
AF						
AG						
OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)						
AH	Anthony, et. al.: "Effects of soy isoflavones on atherosclerosis: potential mechanisms <sup>1-3</sup> " <i>Am J Clin Nutr</i> 1998; (68) (suppl): 1390S-3S					
AI	Greg Peterson and Stephen Barnes: "Genistein inhibition of the growth of human breast cancer cells: Independence from estrogen receptors and the multi-drug resistance gene" <i>Biochemical and Biophysical Research Communications</i> 08/30/91 Vol. 179, No. 1, pages (661-667)					
AJ	Lee-Jane W Lu and Karl E. Anderson: "Sex and long-term soy diets affect the metabolism and excretion of soy isoflavones in humans <sup>1-3</sup> " <i>Am J Clin Nutr</i> 1998; (68) (suppl): 1500S-4S					
AK	Zhang, et. al.: "Daidzein and Genistein Glucuronides in Vitro are weakly estrogenic and activate human natural killer cells at nutritionally relevant concentrations <sup>1,2,3</sup> " <i>J. Nutr.</i> 129: 399-405 (1999)					
AL	Mark Messina and Stephen Barnes: "The Role of Soy Products in Reducing Risk of Cancer <sup>1</sup> " <i>Journal of the National Cancer Institute</i> Vol. 83, No. 8, 541-546 (4/17/91)					
AM	Greg Peterson and Stephen Barnes: "Genistein and Biochanin A Inhibit the Growth of Human Prostate Cancer Cells but not Epidermal Growth Factor Receptor Tyrosine Autophosphorylation" <i>The Prostate</i> 22: 335-345 (1993)					
AN	Charland et. al.: "The effects of a soybean extract on tumor growth and metastasis" <i>International Journal of Molecular Medicine</i> 2: 225-228 (1998)					
AO	Kathleen A. Head, N.D. "Ipriflavone: An Important Bone-Building Isoflavone" <i>Alternative Medicine Review</i> Vol. 4, No. 1, 10-22 (1999)					
AP						
AQ						
EXAMINER			DATE CONSIDERED			

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.